Loading...
•
Sep 30, 2021
Voyager Therapeutics Q3 2021 Earnings Report
Voyager Therapeutics reported a net loss for Q3 2021, with collaboration revenue significantly decreasing due to the termination of collaborations with Neurocrine and AbbVie, while making progress in its TRACER platform and GBA1 gene replacement program.
Key Takeaways
Voyager Therapeutics reported a net loss of $25.1 million for the third quarter of 2021, a significant change from the net income of $85.6 million reported for the same period in 2020. The decrease in collaboration revenue was largely due to a reduction of revenue related to research services and cost reimbursements from the collaborations with Neurocrine and AbbVie.
Entered a license option agreement with Pfizer, receiving $30 million upfront with potential for up to $600 million in exercise fees and milestone payments plus royalties.
Identified AAV9 and AAV5 capsid variants with broad CNS tropism and neuronal and glial cell targeting through the TRACER platform.
GBA1 gene therapy preclinical data showed widespread CNS distribution and sustained correction of GCase activity in multiple brain regions in mice.
Collaboration revenue decreased to $1.5 million for Q3 2021, compared to $117.8 million for the same period in 2020, due to the termination of collaborations with Neurocrine and AbbVie.
Revenue by Segment
Forward Guidance
Voyager anticipates cash, cash equivalents, and marketable debt securities will be greater than $130 million at the end of 2021, based on its current operating plan and excluding any potential financing or business development activities in 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...